期刊文献+

国家环境保护“十二五”规划(摘选)(续)

原文传递
导出
摘要 8完善政策措施8.1落实环境目标责任制制定生态文明建设指标体系,纳入地方各级人民政府政绩考核。实行环境保护一票否决制。继续推进主要污染物总量减排考核,探索开展环境质量监督考核。落实环境目标责任制,定期发布主要污染物减排、环境质量、重点流域污染防治规划实施情况等考核结果,
作者 闫淑萍
出处 《河北化工》 2012年第2期8-9,27,共3页 Hebei Chemical Industry
  • 相关文献

参考文献14

  • 1Elke Wiesemanna,Milani Deba,Bernhard Hemmerb,et al.Early iden- tification of interferon-beta responders by exvivo testing in patients with multiple sclerosis[J].Clinieal Immunology,2008,128(3):306- 313.
  • 2Vollmer T, Panitch H, BarOr A, et al. Glatiramer acetate after induc- tion therapy with mitoxantrone in relapsing multiple sclerosis[J]. Multiple Sclerosis, 2008, 14(5) : 663-670.
  • 3Rose J,Watt H,White A, et al.Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody [J].Ann Neurol, 2004, 56: 864-867.
  • 4Kenji Chiba, Hirotoshi Kataoka, Noriyasu Seki, et al. Fingolimod (FTY720), the Sphingsine 1-Phosphate Receptor Modulator, as aNew Therapeutic Drug in Multiple Sclerosis [J].Inflammation and Regeneration,2011,(31):167-174.
  • 5KAPPOS L, RADUE EW, O CONNOR P, et al.A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis[J]. N Engl J Med, 2010, 362(5): 387- 401.
  • 6Gavin Giovannoni, Giancarlo Comi, Stuart Cook, et al. A Place- bo-Controlled Trial of Oral Cladribine for Relapsing Multiple Scle- rosis[J].The New England Journal of Medicine,2010,362:416-426.
  • 7多发性硬化症的治疗药Cladribine在澳大利亚上市[J].齐鲁药事,2010(11):649-649. 被引量:2
  • 8Tan IL, Lycklama a Nijeholt G J, Polman CH,et al.Linomide in the treatment of multiple sclerosis: MRI results from prematurely termi- nated phase-Ⅲ trials [J]. Multiple Sclerosis, 2000,6(2): 99-104.
  • 9Wegner C, Stadelmann C, F'fsrmer R,et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels,inflam- matory demyelination and acute axonal damage in mice with experi- mental autoimmune encephalomyelitis [J]. Journal of Neumimmunol- ogy, 2010,227(1-2):133-143.
  • 10Oral laquinimod for multiple sclerosis treatment significantly re- duced disease activity and disability progression while providing good safety and tolerability (ALLEGRO trial) [2011-10-04] .TEVA press release, www.tevapharm.com.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部